Clinical Competition Candidate
CRESEMBA
CRESEMBA carries substance and product patents, moderate complexity (2/5), and meaningful clinical competition (5/5). The listed expiry window is approximately 20 months away. Active clinical competition may compress the generic entry window.
LOE window
20months
to latest listed patent expiry (March 14, 2028)
Expiry attractiveness: 5/5
Patent profile
Substance patent (listed)
Product / formulation patent (listed)
Use-code patent (none)
Patent count: 6
Complexity score: 2/5
Clinical competition
Score: 5/5
Active trials linked: 70
Phase 2/3 trials: 18
Higher scores indicate more trial activity for this ingredient — a proxy for competitive generic interest.
Drug overview
Active ingredient: ISAVUCONAZONIUM SULFATE
Applicant (NDA holder): ASTELLAS PHARMA US INC
Confidence: High